MX2020004552A - Vacuna potenciadora de celulas t. - Google Patents
Vacuna potenciadora de celulas t.Info
- Publication number
- MX2020004552A MX2020004552A MX2020004552A MX2020004552A MX2020004552A MX 2020004552 A MX2020004552 A MX 2020004552A MX 2020004552 A MX2020004552 A MX 2020004552A MX 2020004552 A MX2020004552 A MX 2020004552A MX 2020004552 A MX2020004552 A MX 2020004552A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- polynucleotides
- vectors
- antigens
- invariant chain
- Prior art date
Links
- 239000003623 enhancer Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 108010028930 invariant chain Proteins 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a polipéptidos que comprenden un fragmento de una cadena invariante de teleósteo fusionada a uno o más antígenos o una cadena invariante de teleósteo fusionada a uno o más antígenos o fragmentos antigénicos de los mismos, un polinucleótido que codifica dichos polipéptidos, vectores que comprenden dichos polinucleótidos, una colección de vectores que comprenden dichos polinucleótidos y el uso de dichos polipéptidos, polinucleótidos, vectores para tratar o prevenir enfermedades, en particular enfermedades tumorales. Los polipéptidos de cadena invariante de teleósteo o fragmentos de los mismos actúan como "potenciadores de células T" que convierten secuencias antigénicas no inmunogénicas en antígenos de células T inmunogénicos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17200036 | 2017-11-03 | ||
| EP17211235 | 2017-12-29 | ||
| PCT/EP2018/080027 WO2019086615A1 (en) | 2017-11-03 | 2018-11-02 | Vaccine t cell enhancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004552A true MX2020004552A (es) | 2020-10-07 |
Family
ID=64332267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004552A MX2020004552A (es) | 2017-11-03 | 2018-11-02 | Vacuna potenciadora de celulas t. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11912743B2 (es) |
| EP (1) | EP3703744A1 (es) |
| JP (2) | JP7386537B2 (es) |
| KR (1) | KR20200076696A (es) |
| CN (1) | CN111670046A (es) |
| AU (1) | AU2018358019B2 (es) |
| BR (1) | BR112020008308A2 (es) |
| CA (1) | CA3078692A1 (es) |
| IL (1) | IL274409B2 (es) |
| MX (1) | MX2020004552A (es) |
| SG (1) | SG11202003799RA (es) |
| WO (1) | WO2019086615A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2021209897A1 (en) * | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| US20230190903A1 (en) * | 2021-12-16 | 2023-06-22 | Janssen Biotech, Inc. | Prostate cancer vaccines and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107723298A (zh) | 2004-01-23 | 2018-02-23 | Msd意大利有限公司 | 黑猩猩腺病毒疫苗载运体 |
| WO2010057501A1 (en) * | 2008-11-21 | 2010-05-27 | Københavns Universitet (University Of Copenhagen) | Priming of an immune response |
| KR101763093B1 (ko) | 2009-02-02 | 2017-07-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도 |
| MX350795B (es) | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares. |
| GB201321384D0 (en) | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| JP6721145B2 (ja) | 2014-07-25 | 2020-07-08 | 国立研究開発法人理化学研究所 | メモリーインバリアントｎｋｔ細胞マーカー |
| SG11202000247SA (en) * | 2017-07-12 | 2020-02-27 | Nouscom Ag | Neoantigen vaccine composition for treatment of cancer |
-
2018
- 2018-11-02 AU AU2018358019A patent/AU2018358019B2/en active Active
- 2018-11-02 MX MX2020004552A patent/MX2020004552A/es unknown
- 2018-11-02 BR BR112020008308-9A patent/BR112020008308A2/pt not_active Application Discontinuation
- 2018-11-02 EP EP18804240.2A patent/EP3703744A1/en active Pending
- 2018-11-02 KR KR1020207013171A patent/KR20200076696A/ko not_active Application Discontinuation
- 2018-11-02 SG SG11202003799RA patent/SG11202003799RA/en unknown
- 2018-11-02 WO PCT/EP2018/080027 patent/WO2019086615A1/en unknown
- 2018-11-02 JP JP2020524616A patent/JP7386537B2/ja active Active
- 2018-11-02 CN CN201880071581.4A patent/CN111670046A/zh active Pending
- 2018-11-02 US US16/761,004 patent/US11912743B2/en active Active
- 2018-11-02 IL IL274409A patent/IL274409B2/en unknown
- 2018-11-02 CA CA3078692A patent/CA3078692A1/en active Pending
-
2023
- 2023-04-11 JP JP2023063975A patent/JP7485422B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018358019B2 (en) | 2023-05-11 |
| JP2023089103A (ja) | 2023-06-27 |
| US11912743B2 (en) | 2024-02-27 |
| JP7485422B2 (ja) | 2024-05-16 |
| IL274409A (en) | 2020-06-30 |
| IL274409B1 (en) | 2023-07-01 |
| KR20200076696A (ko) | 2020-06-29 |
| RU2020115109A (ru) | 2021-12-03 |
| AU2018358019A1 (en) | 2020-04-23 |
| BR112020008308A2 (pt) | 2020-11-17 |
| CN111670046A (zh) | 2020-09-15 |
| JP7386537B2 (ja) | 2023-11-27 |
| EP3703744A1 (en) | 2020-09-09 |
| IL274409B2 (en) | 2023-11-01 |
| RU2020115109A3 (es) | 2021-12-03 |
| WO2019086615A1 (en) | 2019-05-09 |
| JP2021502076A (ja) | 2021-01-28 |
| SG11202003799RA (en) | 2020-05-28 |
| US20210363201A1 (en) | 2021-11-25 |
| CA3078692A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| CO2019010524A2 (es) | Plataforma de identificación de péptidos inmunogénicos basada en población | |
| CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
| BR112017017293A2 (pt) | método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina | |
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| MX2020004552A (es) | Vacuna potenciadora de celulas t. | |
| CR20170079A (es) | Agentes de unión a cd123 y usos de estos | |
| CL2023002252A1 (es) | Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista | |
| CR20170138A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer | |
| CL2015001900A1 (es) | Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. | |
| UY35964A (es) | Anticuerpos humanos para pd?1 | |
| BR112017005833A2 (pt) | vacinas recombinantes fmdv e seus usos | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| PE20160528A1 (es) | Anticuerpos | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
| CO2019014677A2 (es) | Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos | |
| UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
| CO2022003702A2 (es) | Vacunas para vhb y métodos de tratamiento de vhb | |
| UY37100A (es) | Vacunas de fmdv vectorizadas con adenovirus recombinantes y usos de las mismas | |
| CL2019000019A1 (es) | Anticuerpos con baja inmunogenicidad y uso de los mismos | |
| AR095199A1 (es) | Anticuerpos anti-cd52 | |
| BR112018015893A2 (pt) | vacinas de câncer e métodos de tratamento usando as mesmas |